Výsledky vyhledávání

Akademický článek

PEGylation of human interferon-α2b with modified amino acids increases circulation half-life and antiproliferative activity

Autor: Syeda Kiran Shahzadi, Muhammad Abdul Qadir, Nasir Mahmood, Mahmood Ahmed

Publikováno v: Journal of Taibah University for Science, Vol 17, Iss 1 (2023)

Interferon-α2b (IFN-α2b) is used as a therapeutic agent against various types of cancer. In the current research, modified forms of human INF-α2b were produced to investigate the effect of amino acid substitutions on binding to the interferon rece

Externí odkaz: https://doaj.org/article/65302c9f08bb4a63bb5d33e2fbeefdc8

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow

Autor: Fei Xiong, Qi Wang, Guan-hua Wu, Wen-zheng Liu, Bing Wang, Yong-jun Chen

Publikováno v: Biomarker Research, Vol 10, Iss 1, Pp 1-23 (2022)

Abstract Interferon-α2b (IFN-α2b) is a highly active cytokine that belongs to the interferon-α (IFN-α) family. IFN-α2b has beneficial antiviral, antitumour, antiparasitic and immunomodulatory activities. Direct and indirect antiproliferative eff

Externí odkaz: https://doaj.org/article/e16267303c90457eb725154f820f5d6b

Zobrazit plný text záznamu

Akademický článek

Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

Autor: Shashi Bhushan B L, Sunil Wanve, Parshottam Koradia, Vinay Bhomia, Pravin Soni, Sisir Chakraborty, Akash Khobragade, Shashank Joshi, Sanjeev Kumar Mendiratta, Kevin Kumar Kansagra, Anurag Parihar, Sunil Sharma, Jatin Patel

Publikováno v: International Journal of Infectious Diseases, Vol 111, Iss , Pp 281-287 (2021)

Objective: To evaluate the efficacy and safety of pegylated interferon alpha-2b (PEG IFN-α2b) administered in conjunction with the standard of care (SOC) in subjects with moderate coronavirus disease-19 (COVID-19). Methods: In this study, adult subj

Externí odkaz: https://doaj.org/article/4224fcf9b36b4c10afc34d1cc3b29bf7

Zobrazit plný text záznamu

Akademický článek

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study

Autor: Anuja Pandit, Nirav Bhalani, B.L. Shashi Bhushan, Parshottam Koradia, Shweta Gargiya, Vinay Bhomia, Kevinkumar Kansagra

Publikováno v: International Journal of Infectious Diseases, Vol 105, Iss , Pp 516-521 (2021)

Objective: To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. Methods: In this phase 2, randomized, open-label study, adult subjects aged ≥18

Externí odkaz: https://doaj.org/article/db1045fd9fbc4939a9d4129a5d9bf40c

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Therapeutic effectiveness of interferon-α2b against COVID-19 with community-acquired pneumonia : the Ukrainian experience

Autor: Aleksandr Kamyshnyi, Halyna Koval, Olha Kobevko, Mykhailo Buchynskyi, Valentyn Oksenych, Denis Kainov, Katerina Lyubomirskaya, Iryna Kamyshna, Geert Potters, Olena Moshynets

Publikováno v: International journal of molecular sciences
International Journal of Molecular Sciences; Volume 24; Issue 8; Pages: 6887

Despite several targeted antiviral drugs against SARS-CoV-2 currently being available, the application of type I interferons (IFNs) still deserves attention as an alternative antiviral strategy. This study aimed to assess the therapeutic effectivenes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa476f40ea8e0ca6d236e1dd2d76c4c
https://repository.uantwerpen.be/docstore/d:irua:17781

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání